BioMarin Pharmaceutical Financial Statements
BioMarin Pharmaceutical Financial Overview
BioMarin Pharmaceutical's market cap is currently ―. The company's EPS TTM is $0.18; its P/E ratio is 493.49; BioMarin Pharmaceutical is scheduled to report earnings on July 27, 2022, and the estimated EPS forecast is $0.01. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 519.36M | $ 449.81M | $ 408.74M | $ 501.69M | $ 486.03M |
| Gross Profit | $ 402.39M | $ 330.06M | $ 305.20M | $ 374.63M | $ 365.86M |
| EBIT | $ 137.99M | $ -63.32M | $ -42.29M | $ 17.82M | $ 27.03M |
| EBITDA | $ 165.34M | $ -37.34M | $ -15.45M | $ 45.06M | $ 55.02M |
| Net Income Common Stockholders | $ 120.80M | $ -57.90M | $ -36.49M | $ 12.94M | $ 17.37M |
| Balance Sheet | |||||
| Cash, Cash Equivalents and Short-Term Investments | $ 1.01B | $ 1.06B | $ 1.07B | $ 1.08B | $ 1.09B |
| Total Assets | $ 6.06B | $ 6.00B | $ 5.98B | $ 5.90B | $ 5.81B |
| Total Debt | $ 1.08B | $ 1.09B | $ 1.09B | $ 1.09B | $ 1.09B |
| Net Debt | $ 69.95M | $ 29.37M | $ 21.57M | $ 8.66M | $ 1.83M |
| Total Liabilities | $ 1.67B | $ 1.73B | $ 1.71B | $ 1.66B | $ 1.64B |
| Stockholders Equity | $ 4.05B | $ 4.11B | $ 4.16B | $ 4.24B | $ 4.27B |
| Cash Flow | |||||
| Free Cash Flow | $ -76.11M | $ -33.18M | $ 76.70M | $ 56.53M | $ 85.26M |
| Operating Cash Flow | $ -45.43M | $ 11.18M | $ 97.06M | $ 82.78M | $ 113.51M |
| Investing Cash Flow | $ 87.78M | $ -55.42M | $ -119.85M | $ -120.26M | $ -70.79M |
| Financing Cash Flow | $ -25.28M | $ 14.40M | $ -1.03M | $ 10.95M | $ -24.36M |